# SURVIVAL OF PRIMARILY VASCULARIZED MURINE ALLOGRAFTS

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 1989 · $100,539

## Abstract

Based on previous work on this project, the apparent Lyt 2 plus
suppressor cells associated with long-term survival of primarily
vascularized B10.BR cardiac allografts in B10.A mice will be
further investigated.

To facilitate analysis of a large number of mice and provide
sufficient cell numbers for extensive analysis, in vivo preparation
will be employed.  Treatment with a single dose of anti-L3T4
monoclonal antibody abolishes the L3T4-positive (helper
phenotype) spenocytes nearly completely, leaving a predominant
Lyt 2 plus cell effect.  As an initial simple assessment of whether
the suppressor cells are Lyt 2 plus, splenocytes from long-term
recipients that have been treated by anti-L3T4 monoclonal
antibody in vivo will be tested for suppression as third-party cells
in mixed lymphocyte culture-lymphocyte-mediated cytoxicity
(MLC-LMC), with vs. without flow cytometric sorts to remove
Lyt 2 plus cells.  Next, the time after grafting that the suppressor
cells achieve maximum effect will be found by testing splenocytes
from L3T4 treated animals at sequential times after grafting.
Then, to determine more clearly whether the Lyt 2 plus cells are
responsible for the suppression, they will be removed by flow
cytometric sorting from splenocytes at the time of maximum
suppressor effect and directly tested for suppression as third
party cells in MLC-LMC.

The specificity of the action of these cells will be assessed by
testing their effect on MLC-LMC using other stimulator or
responder strains.

The correlation with degree of rejection will be assessed by
studying other strain pairs the produce strong or weak rejection,
and by comparing occasional B10.A recipients that strongly reject
their heart grafts with those that undergo the usual transient
weak rejection.  The effect of these cells in vivo will be further
assessed by testing whether they specifically suppress skin graft
rejection, and, in other tests, priming for MLC-LMC.

The possibility that the suppressor cells may express Ij will be
studied by determining whether MLC-LMC suppression, as
assessed above, is abolished by removal of subsets bearing this
antigen.

## Key facts

- **NIH application ID:** 3126015
- **Project number:** 5R01AI015081-09
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **SAM.gov UEI:** FTMTDMBR29C7
- **Principal Investigator:** JAMES F BURDICK
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $100,539
- **Award type:** 5
- **Project period:** 1980-07-01 → 1990-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3126015

## Citation

> US National Institutes of Health, RePORTER application 3126015, SURVIVAL OF PRIMARILY VASCULARIZED MURINE ALLOGRAFTS (5R01AI015081-09). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3126015. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*